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1. Introduction 
Affective disorders, including major depression, mania and bipolar disorder, represent a 
spectrum of severe psychiatric diseases reflecting a continuum of psychopathological 
symptoms. Starting in young adulthood and often leading to suicidal ideation, affective 
disorders are ranking among the most disabling diseases worldwide in terms of the WHO 
global burden of disease, are socio-economically relevant, severe and prevalent. These 
diseases lead to enormous social disabilities due to affective and cognitive symptoms [1]. 
Depression, for example, has a lifetime risk of about 20-25% [2] and, besides suicide, a 
higher prevalence of the metabolic syndrome including coronary heart disease and diabetes 
increase mortality [3]. Bipolar disorder with manic episodes, in contrast, has a lifetime 
prevalence of about 1-5% [4]. However, due to the occurrence of depressive symptoms, the 
disease may be misdiagnosed - Goldberg et al. [5] could show a hypo-manic or manic 
episode in 46% in patients with depression. 
Despite tremendous efforts, the neurobiological background of affective disorders remains 
elusive, and due to lacking biomarkers an early diagnosis and reliable prognosis is difficult. 
Undisputed is a multifactorial etiology with genetic and psychosocial factors such as stress, 
emotional trauma and viral infections during the vulnerable episodes of brain development. 
They possibly interact in inducing disease symptoms. Beside neuroendocrinological factors, 
neurotransmitter disturbances and alterations of signal transduction constitute the basis of 
structural and functional alterations in neuronal circuits of the brain. 
2. Neuroimaging studies in affective diseases 
Since the description of the limbic “Papez-circuit of emotion” in the 1930s involving 
hippocampus, cingulated gyrus, anterior thalamus and hypothalamus, magnetic resonance 
 Psychiatric Disorders – New Frontiers in Affective Disorders 4 
imaging [6] studies in patients revealed volume deficits in regions relevant for emotion 
processing, be it amygdala, hippocampus, anterior cingulate gyrus, prefrontal, or 
orbitofrontal cortex as well as basal ganglia. In bipolar disorder, affective and psychotic 
symptoms are related to a dysfunction in the prefrontal-subcortical network interacting with 
limbic regions [7]. Meta-analyses in bipolar disorder indeed show gray matter reductions in 
the paralimbic regions anterior cingulate cortex and insula, partially overlapping with 
decreased volumes in schizophrenia and indicating a continuum of the neurobiological 
background of psychoses [8, 9]. Anterior cingulate dysfunction in bipolar disorder has been 
strengthened by functional MRI studies, which revealed functional attenuation in the 
anterior cingulated cortex in patients with bipolar disorder performing cognitive and 
emotional tasks [10, 11]. Recent meta-analyses of fMRI studies in bipolar disorder show 
decreased activation of the inferior frontal cortex corresponding to frontal hypoactivity and 
overactivated hippocampus plus amygdala (limbic hyperactivity), which was consistent 
across emotional and cognitive tasks and related to the state of mania [12, 13]. Reduced 
fractional anisotropy nearby the parahippocampal gyrus and anterior cingulate cortex have 
been identified in diffusion-tensor imaging studies in bipolar disorder and speak for 
impaired limbic connectivity in neuronal networks [14]. With respect to amygdala size, 
decreased volumes have only been detected in younger patients and a respective correlation 
between volume and age has been reported [15, 16]. Contrastingly, schizophrenia patients 
showed larger ventricles and smaller amygdala volumes compared to bipolar disorder, 
pointing to a continuum of neurobiological alterations [8]. 
Compared to patients with bipolar disorder, those with major depressive disorders present 
decreased rates of white matter hyperintensity, smaller hippocampal and basal ganglia 
volumes and a decreased corpus callosum area [17, 18]. Along with increased lateral 
ventricles, smaller volumes of the basal ganglia, hippocampus, thalamus, frontal lobe, 
orbitofrontal gyrus and gyrus rectus have been detected in major depression [19]. This 
especially pertained patients during depressive episodes with smaller hippocampal 
volumes compared to remittend patients [18]. Reduced hippocampal volumes have 
consistently been reported in patients with major depression and are prominent in patients 
with recurrent and chronic depression [20]. Shape analysis revealed deformations in the 
subiculum, CA1 and CA2-3 subfields in the tail of the right hippocampus of patients with 
first episode of depression [21]. The presence of alterations in first-episode depression is 
consistent with a neurodevelopmental hypothesis of early stress experience, especially since 
this region plays a major role in inhibiting stress response [22], providing inhibitory 
feedback to the hypothalamic-pituitary-adrenal (HPA) axis [23]. 
3. Synaptic plasticity and stress mediation 
Post-mortem investigations reveal reduced density and size of interneurons in cornu 
ammonis (CA) 2/3 subfield of the hippocampus in bipolar disorder [24]. In the hippocampal 
subiculum, a decreased density of neuronal dendrites leading to disturbances of 
microconnectivity and probably representing the basis of the reported volume deficit in 
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bipolar patients has been found [25]. However, the finding of decreased neuropil (dendrites 
and axons) seems not to be specific for bipolar disorder, as it has also been reported in all 
hippocampal subfields of patients with major depression showing increased density of 
neurons and glia cells as a sign of increased packing of the cells. Additionally, in line with the 
hypothesis of a degenerative process, soma size of pyramidal neurons was decreased [26]. In 
the prefrontal cortex of patients with major depression, a decrease in cortical thickness goes 
along with lower densities of neurons and glia cells [27]. In the anterior cingulate cortex, in 
familial depression and bipolar disorder, decreased glia number has been detected [28]. In 
both regions, decrease of glia density and neuronal size has been reported [29]. Decreased glia 
density has also been found in the amygdala of patients with major depression [30]. In animal 
studies again, chronic stress or repeated administration of glucocorticoids interestingly results 
in degeneration of hippocampal neurons with decreased soma size and atrophy of dendrites 
[31, 32]. Stress possibly also influences synaptic plasticity in the prefrontal cortex [33]. Thus the 
volume loss in brain regions like the hippocampus reported in affective disorders may indeed 
be mediated by stress-induced glucocorticoid neurotoxicity [34, 35]. 
Division and differentiation of stem cells to neurons and their migration to the granule cell 
layer has been demonstrated in the hippocampal dentate gyrus of both humans and adult 
rodents [36]. Some factors influence this neurogenesis: While blockade of the glutamatergic 
N-methyl-D-aspartate (NMDA) receptor and adrenalectomy results in increased production 
of granule neurons, adrenal steroids and NMDA receptor activation diminished 
neurogenesis [37]. Acute, chronic or prenatal stress, all of them implicated in the 
pathophysiology of depression [38], have been shown to inhibit proliferation of subgranular 
neurons [39-42]. Because both, circulating adrenal steroids and glutamate-induced 
excitatory input to the hippocampus, are enhanced by stress [43, 44], the influence of 
stressful events on cell proliferation and survival of newly generated neurons may be 
mediated by these mechanisms [40, 45]. In an animal model of learned helplessness, 
inescapable stress is leading to downregulation of neurogenesis [46]. Accordingly, 
antidepressants are known to induce cell proliferation and neurogenesis [46-49]. 
4. Neurotrophins and the HPA axis 
Neurotrophic factors, particulary Brain-Derived Neurotrophic Factor (BDNF) are expressed 
in the hippocampus and cortex and are involved in neurogenesis and synaptic plasticity 
such as promotion of survival and differentiation as well as branching of axons and 
dendrites [50]. In patients with bipolar disorder, reduced hippocampal expression of BDNF 
has been reported [51] while antidepressants reversed this effect [52]. In blood of depressed 
patients, including patients with bipolar disorder, BDNF levels have been found to be 
decreased and correlated to higher depression evaluation scores [53, 54]. Post-mortem 
studies of the hippocampus in major depression revealed a reduced BDNF 
immunhistochemistry [51].  
To date, beside a genetic vulnerability, stress is widely accepted as risk factor for depression. 
In animal models, acute or chronic stress decreased BDNF levels in the hippocampus 
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inclusive the dentate gyrus [52]. Along with this hypothesis, stress is known to reduce the 
branching of hippocampal dendrites [55]. It additionally increases plasma and adrenal 
corticosterone levels and application of this hormone induces reduced hippocampal BDNF 
levels, mimicking stress reaction [52]. The major stress system of the body is the HPA axis, a 
neuroendocrine system involved in the production of the stress hormone cortisol by adrenal 
glands. In more than 50% of patients with major depression, a dysfunction of the HPA axis 
with increased basal cortisol levels and dexamethasone non-suppression of cortisol was 
detected, suggesting abnormal negative feedback system of the HPA axis. Additionally, the 
production of corticotrophin-releasing hormone (CRH) production is abnormal while 
pituitary and adrenal sensitivity seem to be intact [56] (figure 1). CRH is produced in the 
paraventricular nucleus of the hypothalamus in response to psychosocial stress and 
activates the HPA axis. It is binding in the pituitary gland to induce release of 
adrenocorticotropine hormone (ACTH), which in turn stimulates the release of cortisol from 
the adrenal gland. In a negative feedback loop, cortisol binding inhibits CRH and ACTH 
release, inhibiting the HPA axis [57], but this hormonal feedback is known to be abnormal in 
depression. In animal models, CRH administration and overexpression induce depression-
like behavior, while CRH antagonists have antidepressant properties [58, 59]. Depressed 
patients with history of childhood abuse have enhanced HPA axis response to psychosocial 
stress and attenuated adrenocorticotrophin and cortisol response to application of the 
synthetic corticosteroid dexamethasone [60]. However, individual genetic background 
influences the incidence of depression in response to psychosocial stress and only a minority 
of persons exposed to common stressors develops depression [61]. Thus, genes may 
modulate the association between environmental factors like stress and risk of illness. 
5. Genetic findings 
Twin, family and adoption studies have shown that major depression is a moderate 
heritable disease. During the last years, candidate gene and genome-wide association 
studies (GWAS) have linked common DNA sequence variation, called polymorphisms, to 
major depression [62-64] and identified novel candidate loci [65]. However, single 
nucleotide polymorphisms (SNPs) only slightly affect the pathophysiology, and affective 
disorders seem to be of complex polygenetic origin. With respect to CRH dysfunction, a 
genetic variation of the corticotropin releasing hormone type 1 receptor (CRHR1) has been 
found to be associated with decreased HPA axis response to CRH infusion, suggesting to 
influence this pathophysiology of depression [66]. In addition, negative feedback control on 
CRH secretion may be impaired due to altered glucocorticoid receptor (GR) function on 
hippocampal level [67]. A GR polymorphism has also been found to be associated with 
vulnerability to depression [68]. According to the neurotrophin hypothesis, in patients with 
depression and healthy controls, smaller hippocampal volumes have been detected in 
carriers of the BDNF Met66 allele compared to Val/Val homozygotes [69]. These results 
suggest that a Val66Met polymorphism may possibly predispose to smaller hippocampal 
volumes and depression, although this topic currently is under debate [70]. An interaction 
between a 5-HTTLPR serotonin transporter polymorphism and Val66Met BDNF gene 
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variant has been shown to be associated to stress-induced depression [71-73]. Furthermore, 
depression has been associated with polymorphisms in the glucocorticoid receptor gene 
NR3C1, the monoamine oxidase A gene, and genes for glycogen synthase kinase-3ß, a 
neuron-specific neutral amino acid transporter (SLC6A15) as well as group-2 metabotropic 
glutamate receptor (GRM3) [74, 75].  
 
Figure 1.  
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Several other genes are associated with bipolar disorder inclusive brain-derived 
neurotrophic factor (BDNF), D-amino acid oxidase activator (DAOA, G72), disrupted in 
schizophrenia 1 (DISC1), solute carrier family 6 (SLC6A4), tryptophan hydroxylase 2 
(TPH2), catechol-O-methyltransferase (COMT), serotonin transporter (5-HTT) [76-81], but 
there is a large overlap with schizophrenia-associated genes, pointing to a continuum 
between affective disorders and psychosis. Among the risk variants for bipolar disorder, to 
date G72 is the most supported locus [76, 82-84]. However, there is also evidence for an 
association with depression and panic disorder [78, 85]. Additionally, G72 possibly 
influences a predisposition for affective symptoms in schizophrenia [83]. A further risk gene 
for bipolar disorder and depression is diacylglycerol kinase (DGKH), showing 10 SNPs to be 
associated with bipolar disorder while 7 SNPs are associated with unipolar depression and 
four SNPs with ADHD, thus influencing mood instability [86]. Additionally, a region of 
both ankyrin 3 (ANK3) and neurocan (NCAN) has been found to be associated with bipolar 
disorder [65, 87]. A recent meta-analysis revealed association of two SNPs in the serotonin 
1A receptor gene with major depression and bipolar disorder and supports the hypothesis 
of disturbed serotonin neurotransmission in mood disorder [88]. 
Altogether, the heritability of major depression seems to be meager compared to bipolar 
disorder and schizophrenia, which show heritability rates of up to 80%. To date, GWAS 
studies could not identify many reproducible individual gene loci associated with affective 
disorders [89], but SNPs near exons exhibit a greater probability of replication, supporting 
an enrichment of reproducible associations near functional regions of genes [90]. However, 
the confirmation of some loci affords larger samples. In a GWAS study from the GWAS 
consortium Bipolar Disorder Working Group, in large cohorts evidence for association of 
CACN1C, an L-type voltage-gated calcium channel has been confirmed [91]. In order to 
improve methodological quality, new investigations using next-generation sequencing are 
under way.  
Epigenetic mechanisms altering chromatin structure such as histone acetylation and DNA 
methylation may link effects of environmental factors such as stress to transcriptional 
regulation of specific genes. Depression-like behavior and antidepressant action have been 
found to be regulated by epigenetic mechanisms [92]. Besides downregulation of BDNF 
transcripts, stress increased histone methylation at their corresponding promoters. The 
antidepressant imipramine reversed the decrease on the mRNA level and increased histone 
acetylation along with downregulation of histone deacetylase, suggesting an important role 
in histone remodeling in the pathophysiology and treatment of depression [93]. As a 
consequence, new treatment strategies influencing epigenetic targets could be developed. 
6. Neurotransmitter hypotheses 
Selective antidepressant treatment is known to act on the serotonergic and the 
noradrenergic system. Traditional long-term antidepressant treatment is known to induce 
increased levels of serotonin from the raphe nuclei [94]. The serotonin hypothesis of 
depression suggests that decreased serotonin activity increases vulnerability for depression 
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[95]. The serotonin system originates from the dorsal and medial raphe nuclei in the 
brainstem infringing on limbic structures such as the hippocampus and amygdala [94]. 
Reducing serotonin synthesis induces depressive symptoms in healthy probands exposed to 
uncontrollable stress [96], and increased serotonin release in the hippocampus has been 
implicated in the mechanisms underlying coping with stress [97]. Serotonin (5-HT) receptors 
are represented by 5-HT1 class receptors, being situated pre- and postsynaptically and 
inhibitory by reduction of adenylate cyclase activity. The 5-HT2 class excitatory receptors are 
located predominantly postsynaptically through activation of phospholipase C [94]. 5-HT1A 
receptors are known to mediate adaption to stress and these receptors located in the 
hippocampus could attenuate the emotional impact of aversive stimuli, inhibiting the 
consolidation of stressfull memories [97]. Additionally, 5-HT1A receptors are known to 
mediate the serotonin-based increase in neurogenesis [98] and induce release of 
neurotrophic factors [99]. Moreover, serotonin is involved in the regulation of the HPA axis 
[100]. The downregulation of 5-HT1A receptors in the hippocampus by stressors is corticoid-
dependent and reversed by antidepressants [101, 102]. Indeed, patients with depression 
have reduced 5-HT1A receptor binding as revealed by positron emission tomography (PET) 
studies [103, 104] plus results of altered receptor number in post-mortem investigations [105, 
106]. 
The noradrenaline system derives from the locus coeruleus and lateral tegmental nuclei. The 
receptors belong to the excitatory postsynaptic ß-adrenergic, α1 and inhibitory pre- and 
postsynaptic α2 adrenergic categories. They have been shown to be upregulated in post-
mortem brains of patients with depression [95, 107], suggesting a primary noradrenaline 
deficit. Stressors and glucocorticoids persistently activate the noradrenergic system in the 
locus coeruleus with resulting disrupted responses to brief stimuli [94]. In contrast to the 
posterior hippocampus, facilitation of noradrenergic transmission in the ventral 
hippocampus, being involved in emotion and anxiety [108, 109], seems to protect against 
stress effects [110]. Moreover, the noradrenaline system closely interacts with serotonin, 
facilitating serotonin neurotransmission in the hippocampus and amygdala [97] thus 
providing a therapeutic target for antidepressant drugs such as noradrenaline reuptake 
inhibitors [111]. Dopamine is another monoamine proposed to play a role in mood disorder 
since the mesolimbic dopamine reward circuit originating from the ventral tegmental area is 
associated with rewarding effects of food, sex and drug abuse. A dopaminergic deficit may 
contribute to anhedonia reduced motivation and energy level in patients with depression 
and may represent a target for the development of new therapeutic strategies [112]. It is 
expected that reuptake inhibitors for all three catecholamines (serotonin, noradrenaline, 
dopamine) can produce greater efficacy than traditional antidepressants [113]. 
It has been shown that 5-HT depletion alone does not induce mood symptoms, but an 
interaction with glutamate may be responsible for developing affective disorders. 
Additionally, noradrenaline is involved in release and uptake of glutamate [114]. Glutamate 
is the principal excitatory, γ-aminobutyric acid (GABA) the predominant inhibitory 
neurotransmitter in the brain, both occupying at least 50% of the synapses. Besides 
regulating synaptic plasticity, they closely interact with the HPA axis. In depression, an 
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overactive glutamate system and hypoactive GABA system has been suggested [115]. 
Elevated levels of glutamine/glutamate have been shown in MR-spectroscopy (MRS) studies 
in the frontal and occipital cortex as well as in basal ganglia of patients with depression. In 
the anterior cingulate cortex, reduced levels have been reported in depression, while in 
bipolar disorder with acute mania, glutamate/glutamine levels were increased [28]. These 
findings are consistent with glutamatergic overactivity in acute mania. However, 
medication effects may contribute to the findings in mood disorder. In medication-free 
depressed patients, GABA levels have been found to be reduced in the occipital and anterior 
cingulate cortex as well as prefrontal cortex [115]. In clinical studies, agonists at the glycine 
site of the glutamatergic N-methyl-D-aspartate (NMDA) receptor as well as inhibitors of the 
glycine transporter elevating glycine levels have been found to exert antidepressant 
properties. But also antagonists at the NMDA receptor like ketamine induce a presynaptic 
release of glutamate, which in turn activates glutamatergic α-amino-3-hydroxy-5-methyl-
isoxazole-4-propionic acid (AMPA) receptors act as antidepressants [116-118]. Novel 
potential therapeutic drugs affecting the glutamate system are under investigation, such as 
modulators of AMPA receptors, NMDA receptor subunit NR2B, metabotropic glutamate 
receptors, glutamate transporter EAAT2, and N-acetyl-L-cysteine which is a precursor of the 
NMDA receptor activating antioxidant glutathione [117, 119].  
7. Findings on the molecular level 
The above described neurotransmitters are known to modulate gene transcription and 
protein synthesis [120]. Proteomic studies in the frontal cortex and nucleus accumbens of 
depressed patients revealed altered expression of Dihydropyrimidinase-related protein 2 
(DPYSL2), regulating neuronal development, migration and differentiation as well as 
differential expression of aldolase C (ALDOC), which plays a major role in glucose and 
energy metabolism [121]. In the dorsolateral prefrontal cortex, proteomic profiles and a 
phosphoproteomic approach showed differences in proteins associated with synaptic 
transmission and cellular architecture [122] [123]. In bipolar disorder, dysregulation of 
DPYSL2 and glial fibrillary acid protein (GFAP) along with tubulin subunits suggest 
cytoskeletal dysfunction and altered brain development [121].  
Genome-wide gene expression studies in bipolar disorder unearthed a high correlation of 
expression changes also observed in schizophrenia such as decreased oligodendrocyte and 
myelination related genes, as well as deregulation of mitochondrial energy metabolism, 
oxidative phosphorylation, synapse-related and mitochondrial genes [124, 125]. In 
depressed patients, alterations of genes involved in neurodevelopment, signal transduction, 
cell communication and myelination have been reported. Additionally, genes encoding for 
the glutamate and serotonin system have been found to be altered in bipolar disorder and 
depression [125]. Moreover, in mood disorder, alterations of BDNF and subunits of 
glutamate receptors and the GABA synthesizing enzyme GAD have been detected to be 
differentially regulated [126]. In a previous laser-capture microdissection study of the locus 
coeruleus, Bernard [127] found alterations of the glutamate-, astroglia- and growth factor 
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related genes in depression, but not in bipolar disorder, suggesting differential processes in 
both disorders. In the frontal cortex of patients with major depression, increased apoptosis 
stress and upregulation of pro-and anti-inflammatory cytokines have been detected [128] 
which differs from findings in schizophrenia [129]. Interestingly, in an animal study, chronic 
stress affected expression of genes involved in brain development, morphogenesis and 
synaptic transmission in the dentate gyrus of the hippocampus, which is involved in 
neurogenesis [130]. Modulation of these stress effects may lead to development of new 
therapeutic strategies for mood disorder. 
8. Conclusion 
Overall, mood disorder entails a broad spectrum of alterations in specific neuronal circuits. 
Despite overlapping findings in patients with major depression, bipolar disorder and even 
schizophrenia, pointing to a neurobiological continuum of the diagnostic spectrum of 
psychoses, specific findings can be detected on the cellular, molecular and hormonal level. 
Besides genetics, environmental factors like acute or chronic stress are known to account for 
the pathophysiology of the named disorders. New treatment strategies involving several 
neurotransmitter systems are under way and may improve outcome. However, preventive 
and cause-related treatments based on molecular findings plus animal studies of 
environmental and genetic factors should be developed to increase efficacy and prevent 
burden of severe psychiatric diseases. 
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